Thermo Fisher Scientific Inc. $TMO Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,454 shares of the medical research company’s stock after selling 2,364 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $20,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Cullen Frost Bankers Inc. grew its position in shares of Thermo Fisher Scientific by 8.4% during the third quarter. Cullen Frost Bankers Inc. now owns 35,558 shares of the medical research company’s stock worth $17,246,000 after buying an additional 2,769 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in Thermo Fisher Scientific by 33.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 55,663 shares of the medical research company’s stock valued at $26,998,000 after purchasing an additional 13,904 shares during the last quarter. Whittier Trust Co. grew its position in shares of Thermo Fisher Scientific by 28.6% in the 3rd quarter. Whittier Trust Co. now owns 119,518 shares of the medical research company’s stock valued at $57,969,000 after buying an additional 26,584 shares during the last quarter. Quilter Plc raised its stake in Thermo Fisher Scientific by 1.0% during the 3rd quarter. Quilter Plc now owns 278,786 shares of the medical research company’s stock worth $135,217,000 after acquiring an additional 2,675 shares in the last quarter. Finally, Frazier Financial Advisors LLC boosted its stake in Thermo Fisher Scientific by 30.5% in the third quarter. Frazier Financial Advisors LLC now owns 107 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $625.42 on Monday. The company has a 50 day moving average of $590.88 and a two-hundred day moving average of $532.39. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a market cap of $234.98 billion, a P/E ratio of 36.13, a P/E/G ratio of 4.11 and a beta of 0.91.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were paid a dividend of $0.43 per share. The ex-dividend date was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock buyback plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

TMO has been the subject of several research reports. Evercore ISI reissued an “outperform” rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. UBS Group increased their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. Finally, KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a report on Sunday, December 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $625.47.

Insiders Place Their Bets

In other news, COO Michel Lagarde sold 22,046 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the transaction, the chief operating officer owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the completion of the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. This represents a 32.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 124,517 shares of company stock valued at $72,363,568 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.